AstraZeneca PLC Stock price

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 04:07:55 22/02/2024 pm IST 5-day change 1st Jan Change
9,902 GBX -0.44% Intraday chart for AstraZeneca PLC +0.84% -6.52%
Sales 2024 * 50.9B 4,215B Sales 2025 * 54.58B 4,519B Capitalization 198B 16,368B
Net income 2024 * 9.04B 748B Net income 2025 * 9.85B 816B EV / Sales 2024 * 4.24 x
Net Debt 2024 * 18B 1,491B Net Debt 2025 * 12.07B 1T EV / Sales 2025 * 3.84 x
P/E ratio 2024 *
22.3 x
P/E ratio 2025 *
19.1 x
Employees 83,500
Yield 2024 *
2.45%
Yield 2025 *
2.56%
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.45%
1 week+0.84%
Current month-5.63%
1 month-6.44%
3 months-1.76%
6 months-7.38%
Current year-6.52%
More quotes
1 week
9 849.00
Extreme 9849
10 498.00
1 month
9 461.00
Extreme 9461
10 682.00
Current year
9 461.00
Extreme 9461
11 022.00
1 year
9 461.00
Extreme 9461
12 392.00
3 years
6 736.00
Extreme 6736
12 392.00
5 years
5 626.00
Extreme 5626
12 392.00
10 years
3 680.00
Extreme 3680
12 392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/12/01
Director of Finance/CFO 50 01/21/01
Chief Tech/Sci/R&D Officer 56 01/20/01
Members of the board TitleAgeSince
Director/Board Member 65 01/17/01
Corporate Officer/Principal 59 01/13/01
Director/Board Member 63 27/17/27
More insiders
Date Price Change Volume
22/24/22 9,909 -0.37% 244 892
21/24/21 10,102 -1.00% 1,580,412
20/24/20 10,204 -2.05% 2,386,943
19/24/19 10,418 +3.21% 1,881,312
16/24/16 10,094 +2.73% 2,703,768

Delayed Quote London S.E., February 22, 2024 at 03:52 pm IST

More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
127.5 USD
Average target price
161.8 USD
Spread / Average Target
+26.84%
Consensus
1st Jan change Capi.
-6.52% 198 B $
+27.96% 671 B $
+21.53% 538 B $
+1.24% 382 B $
+17.52% 325 B $
+13.02% 309 B $
-5.93% 211 B $
+6.40% 209 B $
-3.89% 156 B $
-1.58% 152 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer